Literature DB >> 25716461

Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.

Ali A Ghazi1, Fabio Rotondo, Kalman Kovacs, Alireza Amirbaigloo, Luis V Syro, Hussein Fathalla, Antonio Di Ieva, Michael D Cusimano.   

Abstract

Improved imaging techniques have contributed to increased diagnosis of pituitary tumors. These tumor types can be microadenomas or macroadenomas and can either be functional or non-functional. Atypical or aggressive pituitary adenomas are tumors that rapidly increase in size and may invade into the suprasellar or parasellar regions. They are characterized by a Ki-67 nuclear labeling index greater than 10 %. Management of these tumors is difficult, and many recur after surgery. Temozolomide, a second generation alkylating agent, has been showing promising results in the treatment of these tumors. The patient was a 39-year-old male diagnosed with an invasive silent somatotroph pituitary macroadenoma treated with temozolomide after surgery. We present the case along with the review of the literature of the therapeutic effects of temozolomide in somatotroph macroadenomas.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25716461     DOI: 10.1007/s12022-015-9361-z

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  28 in total

Review 1.  Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.

Authors:  Gérald Raverot; Frédéric Castinetti; Emmanuel Jouanneau; Isabelle Morange; Dominique Figarella-Branger; Henry Dufour; Jacqueline Trouillas; Thierry Brue
Journal:  Clin Endocrinol (Oxf)       Date:  2012-06       Impact factor: 3.478

2.  Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.

Authors:  Marco Losa; Elena Mazza; Maria Rosa Terreni; Ann McCormack; Anthony J Gill; Micaela Motta; Maria Giulia Cangi; Anna Talarico; Pietro Mortini; Michele Reni
Journal:  Eur J Endocrinol       Date:  2010-09-24       Impact factor: 6.664

Review 3.  Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.

Authors:  S S Agarwala; J M Kirkwood
Journal:  Oncologist       Date:  2000

4.  MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.

Authors:  Sayid Shafi Zuhur; Canan Tanik; Özcan Karaman; Selvinaz Velet; Esra Çil; Feyza Yener Öztürk; Hanife Özkayalar; Ahmet Murat Müslüman; Yüksel Altuntaş
Journal:  Endocrine       Date:  2011-05-15       Impact factor: 3.633

5.  Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression.

Authors:  Zachary M Bush; Janina A Longtine; Tracy Cunningham; David Schiff; John A Jane; Mary Lee Vance; Michael O Thorner; Edward R Laws; M Beatriz S Lopes
Journal:  J Clin Endocrinol Metab       Date:  2010-07-28       Impact factor: 5.958

Review 6.  Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.

Authors:  Gerald Raverot; Emmanuel Jouanneau; Jacqueline Trouillas
Journal:  Eur J Endocrinol       Date:  2014-03-13       Impact factor: 6.664

Review 7.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

Review 8.  Practical pituitary pathology: what does the pathologist need to know?

Authors:  Sylvia L Asa
Journal:  Arch Pathol Lab Med       Date:  2008-08       Impact factor: 5.534

Review 9.  Aggressive pituitary adenomas--diagnosis and emerging treatments.

Authors:  Antonio Di Ieva; Fabio Rotondo; Luis V Syro; Michael D Cusimano; Kalman Kovacs
Journal:  Nat Rev Endocrinol       Date:  2014-05-13       Impact factor: 43.330

Review 10.  Genomic approaches to problems in pituitary neoplasia.

Authors:  Sylvia L Asa; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

View more
  3 in total

Review 1.  Silent somatotroph pituitary adenomas: an update.

Authors:  Fabienne Langlois; Randall Woltjer; Justin S Cetas; Maria Fleseriu
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

2.  Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Elena Varlamov; Chris G Yedinak; Justin S Cetas; Shirley McCartney; Aclan Dogan; Maria Fleseriu
Journal:  Endocrine       Date:  2017-10-17       Impact factor: 3.633

Review 3.  Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas with Adjuvant Temozolomide Chemotherapy: A Review.

Authors:  Marc Moisi; Aurora S Cruz; Tara Benkers; Steven Rostad; Frances Broyles Broyles; Kevin Yuen; Marc Mayberg
Journal:  Cureus       Date:  2016-06-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.